Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction.
Mojun ZhuChunhua ChenNathan R FosterChristopher HartleyTaofic MounajjedMarcela A SalomaoBriant F FruthStaci E BeamerYohan KimSusan M HarringtonHenry C PitotCristobal T SanhuezaYening FengJoerg HerrmannRobert R McWilliamsFabrice LucienBing Q HuangWen Wee MaTanios S Bekaii-SaabHaidong DongDennis WigleDaniel H AhnChris L HallemeierShanda H BlackmonHarry H YoonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Adding pembrolizumab to trimodality therapy showed acceptable tolerability but did not meet the pre-specified pCR endpoint. Exploratory analyses suggested that high PD-L1 expression in the TME and/or on EVs may identify patients most likely to achieve tumor response.
Keyphrases
- locally advanced
- rectal cancer
- end stage renal disease
- squamous cell carcinoma
- ejection fraction
- newly diagnosed
- advanced non small cell lung cancer
- chronic kidney disease
- prognostic factors
- lymph node
- radiation therapy
- randomized controlled trial
- open label
- stem cells
- patient reported outcomes
- bone marrow
- study protocol